Condition: Glioblastoma, IDH-wildtype · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The study aims at: 1. Perform a multilayer analysis relying on tight integration of in-depth multi-omics approaches with clinical data to discover immune markers, with attention to age and sex differences, predicting prognosis and defining key life/environmental elements, to guide AI-driven personalised treatments and ensure improved care and QoL of glioblastoma patients. 2. To deepen glioblastoma knowledge through the study of glioblastoma stem cell cultures and to assess the sensitivity of glioblastoma stem cell cultures to a number of chemotherapeutics in different experimental conditions. 3. To create a comprehensive, stakeholder-generated guidelines for the ethical use of patient data for artificial intelligence-assisted prediction systems in glioblastoma, including an online, easily accessible patient information brochure to increase patient empowerment in the field.
This description comes directly from the study's public registry record.
Quintino Giorgio D'Alessandris, MD, PhD · +39 06 30155414 · quintinogiorgio.dalessandris@policlinicogemelli.it
Roberto Pallini, MD, PhD · +39 06 30155414 · roberto.pallini@unicatt.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Universitario A. Gemelli IRCCS | Rome, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05941234